DEK: A novel early screening and prognostic marker for breast cancer
- Authors:
View Affiliations
Affiliations: Interventional Catheter Room, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Toxicology, Harbin Medical University School of Public Health, Harbin, Heilongjiang 150081, P.R. China
- Published online on: September 29, 2015 https://doi.org/10.3892/mmr.2015.4380
-
Pages:
7491-7495
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The present study aimed to investigate the expression status and clinical implications of DEK in breast cancer, in order to contribute to developments in breast cancer management. DEK expression status was detected in 628 breast cancer specimens by western blot analysis and immunohistochemistry staining, and the correlation between DEK protein and clinico‑pathological parameters and prognosis of breast cancer was subsequently determined. In comparison to para-carcinoma tissues, DEK protein was highly expressed in breast cancer specimens and was correlated with chemotherapy resistance. In total, 61.94% (389/628) of breast cancer cases exhibited high expression of DEK. According to universal analysis, it was observed that age, tumor size, histological grade, metastatic nodes and distant metastasis (P=0.024, 0.001, 0.001, 0.001 and 0.001 respectively) are key factors associated with DEK. Furthermore, compared with samples with no or low DEK protein expression, high DEK expression resulted in a significantly increased distant metastasis rate and poor disease‑specific survival (P=0.001). In addition, DEK protein was detected as an independent prognostic factor (P=0.001) in the Cox regression analysis. DEK was correlated with chemotherapy resistance and may be an independent prognostic factor for breast cancer, as well as a potential therapeutic target.
View References
|
1
|
Gaffan J, Dacre J and Jones A: Educating
undergraduate medical students about oncology: a literature review.
J Clin Oncol. 24:1932–1939. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dowling EC, Klabunde C, Patnick J and
Ballard-Barbash R: For the international cancer screening network
(ICSN): Breast and cervical cancer screening programme
implementation in 16 countries. J Med Screen. 17:139–146. 2010.
View Article : Google Scholar
|
|
3
|
Dilaveri CA, Mac Bride MB, Sandhu NP, Neal
L, Ghosh K and Wahner-Roedler DL: Breast manifestations of systemic
diseases. Int J Womens Health. 4:35–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Magee JA, Piskounova E and Morrison SJ:
Cancer stem cells: impact, heterogeneity and uncertainty. Cancer
Cell. 21:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Broxmeyer HE, Mor-Vaknin N, Kappes F,
Legendre M, Saha AK, Ou X, O'Leary H, Capitano M, Cooper S and
Markovitz DM: Concise review: role of DEK in stem/progenitor cell
biology. Stem Cells. 31:1447–1453. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang DM, Liu L, Fan L, Zou ZJ, Zhang LN,
Yang S, Li JY and Xu W: Expression level of DEK in chronic
lymphocytic leukemia is regulated by fludarabine and Nutlin-3
depending on p53 status. Cancer Biol Ther. 13:1522–1528. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Privette Vinnedge LM, Benight NM, Wagh PK,
Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz
SE and Wells SI: The DEK oncogene promotes cellular proliferation
through paracrine Wnt signaling in Ron receptor-positive breast
cancers. Oncogene. 34:2325–2336. 2015. View Article : Google Scholar
|
|
8
|
Adams AK, Hallenbeck GE, Casper KA, Patil
YJ, Wilson KM, Kimple RJ, Lambert PF, Witte DP, Xiao W, Gillison
ML, Wikenheiser-Brokamp KA, et al: DEK promotes HPV-positive and
-negative head and neck cancer cell proliferation. Oncogene.
34:868–877. 2015. View Article : Google Scholar
|
|
9
|
Piao J, Shang Y, Liu S, Piao Y, Cui X, Li
Y and Lin Z: High expression of DEK predicts poor prognosis of
gastric adenocarcinoma. Diagn Pathol. 9:672014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y,
Li J and Lin Z: DEK over expression as an independent biomarker for
poor prognosis in colorectal cancer. BMC Cancer. 13:3662013.
View Article : Google Scholar : PubMed/NCBI
|
